Может ли блокировка андрогенных рецепторов стать основой нового способа лечения трижды негативного рака молочной железы

Triple-negative breast cancer (TNBC) represents approximately 15% –20% of all diagnosed breast cancers. This tumor subtype characterized by the absence of expression of the estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor (HER2) protein. Tumor heterogeneity of triple negative breast cancer is the main barrier in the treatment of this tumor subtype. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments.